JAMA Otol Logo Orlando 2013 AHNS Meeting Location
American Head & Neck Society
Annual Meeting, April 10-11, 2013
JW Marriott Grande Lakes
Orlando, Florida

During the
Combined Otolaryngology Spring Meeting
Tips on Using this Site
Locate an abstract by entering any author's surname into the search box.

Broaden your search by typing only a few letters of a keyword; do not append the wildcard “*” to a search string.

Type too small? In most browsers, press Control “+” to enlarge type size. Reset by pressing Control “0”.

Results. To view an abstract, click on a title within results. Presenters’ names are underlined among the list of authors.

Presentation: P001
Topic: Basic Science - Immunology
Type: Poster
Date: Wednesday - Thursday, April 10 - 11, 2013
Session: Designated Poster viewing times
Authors: Ian-James Malm, Tullia C Bruno, PhD, Mikhail Gorbounov, BA, Janis Taube, MD, Charles Drake, MD, PhD, Young Kim, MD, PhD
Institution(s): Johns Hopkins Medical Institutions

Targeting PD-1/PD-L1 immune checkpoint signaling with a blocking αPD-1 antibody showed efficacy in a recent clinical trial for advanced melanoma, lung cancer, and renal carcinoma. In this trial, the expression of PD-L1 on tumor specimen was found to be a critical biomarker, correlating with the clinical efficacy of PD-1 blockade. However, the expression profile of PD-1/PD-L1 and the potential of PD-1 blockade in non-HPV head and neck squamous cell carcinoma (HNSCC) patients have not been explored in detail.

We harvested CD4+ and CD8+ T cells from the peripheral blood (PBL), draining lymph nodes (DLN) and tumor (TIL) of non-HPV HNSCC patients undergoing surgical ablation treatment. These lymphocytic cells were phenotyped via flow cytometry for PD-1, and its functional activity was assessed with a mixed lymphocyte reaction (MLR) using blocking αPD-1 treatment. Furthermore, we characterized the expression profile of the PD-1 ligand, PD-L1, on HNSCC tumor samples using immunohistochemistry.

FACS analysis revealed significantly increased PD-1 expression on CD4+ and CD8+ T cells from HNSCC patients in all three compartments (PBL, DLN, and TIL), with the highest level of positivity in the TIL. There was significant enrichment of PD-1+ lymphocytes (both CD4 and CD8) in the TIL in comparison to the PBL in all the matched samples analyzed. Of note, 50-80% of tumor infiltrating CD4+ and CD8+ lymphocytes expressed PD-1. Moreover, 15-30% of circulating CD4+ and CD8+ cells expressed PD-1 in comparison to <15% in normal donors. An in vitro mixed lymphocyte reaction of the T cells from the peripheral blood and the tumor microenvironment demonstrated that PD-1 blockade could induce T cell proliferation in both CD4+ and CD8+ T cells, demonstrating the functional ability of PD-1+ cells to suppress T-cells. When we examined archived HNSCC tumor specimens, the tumor cells were found to express PD-L1.

In HNSCC patients, both CD4+ and CD8+ T-cells from all three compartments expressed PD-1, with a significant enhancement of PD-1+ cells in the tumor microenvironment. Moreover, the HNSCC tumor cells expressed PD-L1, a critical biomarker of PD-1 blockade efficacy. Cumulatively, our clinical data strongly supports the introduction of αPD-1 blockade in HNSCC patients that are refractory to standard treatments.

glimepirid prospect sogvitaminer.site glimepirid kosten
lansoprazol 30 mg dosis lansoprazol sandoz lansoprazol stada 15 mg

JAMA Network Logo